Literature DB >> 17043508

Dosing of antirheumatic drugs in renal disease and dialysis.

Areena Swarup1, Namita Sachdeva, H Ralph Schumacher.   

Abstract

Many patients with rheumatic diseases have their management complicated by renal problems. Renal failure modifies the metabolism of many drugs, especially by retention. Questions often arise about the effects of renal failure on the handling of drugs commonly used in rheumatology. For which drugs must we be especially concerned about increased toxicity? Patients on chronic dialysis may also need a variety of drugs for rheumatic disease. How are our drugs dialyzed, and which of these can be safety used and how best to use them?Decisions about dosing of rheumatic drugs are often required for the patients with chronic renal insufficiency or on long-term dialysis, although many drugs have not been formally studied in these settings. Patients with renal insufficiency are excluded from most drug trials. Data for some of these drugs have to be extrapolated based on the information available about the pharmacokinetics of the drug.This review addresses dosing of commonly used drugs in rheumatology in patients with chronic renal insufficiency or failure. It is compiled from a MEDLINE search of papers dealing with renal handling of antirheumatic drugs and suggestions for dose adjustments for these drugs. Drugs reviewed include commonly used disease-modifying antirheumatic drugs (DMARDS), drugs used for treatment of gout, commonly used nonsteroidal antnflammatory drugs (NSAIDS) and the newer COX-2 inhibitors.

Entities:  

Year:  2004        PMID: 17043508     DOI: 10.1097/01.rhu.0000135555.83088.a2

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  6 in total

1.  The efficacy and safety of etanercept in patients with rheumatoid arthritis and spondyloarthropathy on hemodialysis.

Authors:  Soner Senel; Bunyamin Kisacik; Yunus Ugan; Timucin Kasifoglu; Ercan Tunc; Veli Cobankara
Journal:  Clin Rheumatol       Date:  2011-05-28       Impact factor: 2.980

2.  2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis.

Authors:  Dinesh Khanna; Puja P Khanna; John D Fitzgerald; Manjit K Singh; Sangmee Bae; Tuhina Neogi; Michael H Pillinger; Joan Merill; Susan Lee; Shraddha Prakash; Marian Kaldas; Maneesh Gogia; Fernando Perez-Ruiz; Will Taylor; Frédéric Lioté; Hyon Choi; Jasvinder A Singh; Nicola Dalbeth; Sanford Kaplan; Vandana Niyyar; Danielle Jones; Steven A Yarows; Blake Roessler; Gail Kerr; Charles King; Gerald Levy; Daniel E Furst; N Lawrence Edwards; Brian Mandell; H Ralph Schumacher; Mark Robbins; Neil Wenger; Robert Terkeltaub
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-10       Impact factor: 4.794

Review 3.  [Dosage and toxicity of antirheumatic drugs in renal insufficiency].

Authors:  S M Weiner; R Bergner
Journal:  Z Rheumatol       Date:  2015-05       Impact factor: 1.372

4.  [Renal manifestations in rheumatic diseases].

Authors:  K de Groot
Journal:  Internist (Berl)       Date:  2007-08       Impact factor: 0.743

Review 5.  Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis.

Authors:  Bruce N Cronstein; Prashanth Sunkureddi
Journal:  J Clin Rheumatol       Date:  2013-01       Impact factor: 3.517

Review 6.  Renal co-morbidity in patients with rheumatic diseases.

Authors:  Hans-Joachim Anders; Volker Vielhauer
Journal:  Arthritis Res Ther       Date:  2011-06-29       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.